Breast tictoc Pragmatic:Phase2 of chemo+/- Tocilizumab in TNBC and ER-low Breast Cancers - Clinical Trial
¿Cuál es el Propósito de este estudio?
Este estudio tiene tres partes:
1. Getting Ready (Screening)
- Takes up to 28 days
- You'll get blood tests, a tissue sample, a TB test, and health checkups like scans and heart tests.
2. Treatment (Study Dosing)
- People are grouped by race
- You'll be randomly picked to get either regular chemo or chemo plus a study medicine (tocilizumab)
- Medicine is given every 4 weeks
- You'll keep doing health checkups and answer questions.
3. After Treatment (Follow-up)
- Happens within 30 days after your last dose
- More health checkups and questions to see how you're doing.
Adults with metastatic triple negative or Estrogen Receptor (ER)-low breast cancer
¿Quién puede participar en el Estudio?
Who can join the study?
Adults with a certain kind of advanced breast cancer called metastatic triple negative or ER-low can join if they:
- Have had zero or one chemo treatment for their cancer
- Have cancer that doctors can measure
- Are healthy enough to do daily activities (rated as ECOG 0 or 1)
¿Qué Implica?
¿Por qué se está llevando a cabo este estudio?
Doctors want to see if using two medicines together—tocilizumab and regular chemotherapy—works better than just using chemotherapy alone.
They are testing this in Black and non-Black patients who have a certain kind of advanced breast cancer.
Detalles del Estudio
